Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential

8. Exact Sciences Corporation (NASDAQ:EXAS)

Exact Sciences Corporation operates as a cancer screening and diagnostic test products provider. The company provides Cologuard, Oncotype DX Breast DCIS Score Test, OncoExTra Test for tumor profiling, Riskguard Test, Oncotype DX Breast Recurrence Score Test, and Oncotype DX Colon Recurrence Score Test. According to the median analyst price target, the stock still has an upside of 47.23%.

On April 22, the firm announced the launch of its new test, Oncodetect. This new test detects the molecular residual disease (MRD) among multiple solid tumors. According to the company, this test provides clear results, ‘detected’ or ‘not detected’, along with the quantitative data to facilitate treatment.

Brian Baranick, Executive Vice President and General Manager Precision Oncology at Exact Sciences, said:

“Exact Sciences is transforming cancer care by delivering tests that provide the clarity patients and physicians need to make confident decisions,… Advanced detection tools like the Oncodetect test help bridge that gap by providing clinical insights at critical periods, leading to more informed treatment decisions and personalized care.”

RBC Capital Markets started coverage of EXAS last month. The research firm assigned a Sector Perform rating to the stock with a price target of $52, citing growth potential in the oncology screening sector of liquid biopsy.